Leyue Health Secures RMB 115 Million Series B Funding to Advance Healthcare Big Data and InsurTech Solutions

Recently, Leyue Health, a provider of medical big data and health insurance technology services, announced the completion of its RMB 115 million Series B financing round. The round was led by CO-WIN Venture Capital, with follow-on investment from CAS Investment, while Qingtong Capital served as the financial advisor.

“Leyue Health” founder Fu Xinhua stated that, as the pioneer and leader in health insurance data technology in China, “Leyue Health” will further expand its leading advantage in building medical data networks after this round of financing, and comprehensively enhance its data service capabilities across more business scenarios in the health insurance sector.

Previously, “Leyue Health” secured investments from BlueFocus, CAS Investment Management Co., Ltd., Sinovest Capital, and strategic shareholder Sinosoft, with cumulative financing exceeding RMB 100 million.

With the rapid development of the health insurance industry in recent years, the sector has entered a stage of data-driven, refined operations. Digital penetration continues to increase across all aspects, from front-end product design and pricing to back-end risk control and cost management. Since 2016, “Leyue Health” has taken the lead in advancing data intelligence within the commercial health insurance sector. By focusing on commercial insurance settlement and working closely with industry regulators, it has jointly encouraged medical institutions to open up their data. Additionally, it has built its own data platform to provide online services such as intelligent underwriting and claims processing for insurance institutions and patients.

After more than three years of development, “Leyue Health,” a pioneering brand in medical big data and health insurance technology, has become the preferred partner for insurance institutions undergoing digital transformation in the health insurance sector. Leyue’s core strengths lie in its leading medical data acquisition network, strong capability in navigating industrial policy guidance, and proven ability to implement products effectively.

The medical data network currently covers more than 3,000 hospitals at the secondary level and above, meeting 70% of the data needs of China’s domestic health insurance market. High entry barriers, low willingness to share, and inefficient integration of medical data constitute the core challenges facing the industry’s digital transformation. Leveraging decades of accumulated insights into industry resources, the “Leyue Health” team has achieved efficient, comprehensive, and legally compliant access to medical data through close alignment with policies issued by the National Health Commission. This top-down development strategy has established scaled data-source advantages as the core competitive barrier of the Leyue model.

Promoting the implementation of policies related to one-stop settlement platforms for commercial health insurance, we currently provide construction and operational maintenance services for dozens of provincial and municipal platforms. The digital upgrade of commercial insurance settlement meets healthcare institutions’ demands for innovative services, accelerates claims processing upgrades for insurers, and simplifies reimbursement procedures for patients, making it a key component in the steady advancement of healthcare reform and the in-depth implementation of national health policies. “Leyue Health” actively guides policy formulation and collaborates with relevant functional departments to ensure efficient implementation, further strengthening its access to industry data as an infrastructure builder for the sector.

We have essentially established commercial partnerships with the top 20 insurance institutions, and our intelligent risk control and claims settlement product has accumulated tens of millions of data calls. Leveraging big data technologies such as Natural Language Processing (NLP) and knowledge graphs, the “Leyue Health” product achieves automated matching between medical information and insurance rules. It provides insurance institutions with nationwide investigation-based risk control and claims data references, while extending services to front-end business scenarios such as product innovation. In the future, “Leyue Health” will continue to broaden its product line, deliver more comprehensive data service capabilities, and collaborate with insurance companies to achieve a higher level of digitalization at the business level.

Fu Xinhua, founder of “Leyue Health,” stated, “In 2016, when we embarked on the digital and intelligent transformation of commercial insurance, we faced a completely untapped market. After more than three years of exploration and growth, the Leyue model has been preliminarily validated. We focused on three core initiatives: acquiring large-scale medical data, influencing the direction of health policies, and launching our first-phase products. As a pioneer and leading brand in the industry, we will increase our investment in product research and development as well as medical network coverage in the future, delivering more comprehensive data-driven intelligent services to contribute to the refined development of the commercial health insurance sector.”

As the lead investor in this round, Zhang Xin, Vice President of Investment at CO-WIN Venture Capital, stated: “‘Leyue Health’ has the potential to pioneer a new paradigm for the insurance industry. As a former senior insurance regulatory official, I understand the industry’s long-standing pain point and strong desire to integrate medical data. This is an enterprise service project with fintech attributes. By fundamentally transforming the underwriting and claims adjudication processes, it shifts from traditional methods based on statistical patterns to precise measurement enabled by internet-based informatization technologies, thereby planting the first seed for a future where insurance policies are personalized and premiums are individually priced based on specific health profiles.”

Wang Zhenxi, Deputy Investment Director at CAS Investment, a co-investor in this funding round, stated, “From a long-term perspective, the interoperability and online processing of precision medicine data related to commercial health insurance represent an inevitable trend. ‘Leyue Health’ has explored and established a new TPA technology model centered on medical data, focusing on intelligent claims settlement and risk control in underwriting and claims adjudication. This approach not only facilitates industrial upgrading within the insurance sector but also enhances the consumer experience for commercial insurance policyholders. Given the broad application prospects of big data in healthcare, it holds significant commercial and social value.”

As the financial advisor for this round of financing, Pan Mohan, Investment Director at Qingtong Capital, stated, “The commercial health insurance data services sector represents a market worth hundreds of billions of yuan. The industry’s digital transformation requires in-depth collaboration among medical institutions, insurance companies, regulatory authorities, and other stakeholders, marking a long-term yet inevitable developmental trajectory. As an early-mover data technology service provider in the industry, ‘Leyue Health’ has evolved into a leading enterprise with strong business barriers in its niche segment, leveraging its years of accumulated resources in the healthcare sector, its independent third-party status, and its large-scale data network. We look forward to ‘Leyue Health’ continuing to empower the digital upgrade of the commercial health insurance industry in the future.”